Since HER2 is a key determinant of the levels of the HER23 heterodimers and other downstream targets measured in the HER3/PI3K pathway in the breast cancer cell lines we studied, therapeutic inhibition of HER2 should be reflected in the inhibition of this pathway. The gene discussed is ERBB2; the disease is breast carcinoma.